4 Likes
KarXT demonstrated statistically significant and clinically meaningful improvements in primary and key secondary efficacy measures compared with placebo
Incidences of somnolence, weight gain and extrapyramidal symptoms were similar in KarXT and placebo treatment groups
KarXT is in Phase 3 clinical development for the treatment of psychosis in adults with schizophrenia
5 Likes
This topic was automatically closed 90 days after the last reply. New replies are no longer allowed.